Saher Saeed, Ioannis Dimopoulos, Nehara Begum, Jan Robert Kröger
{"title":"Intrapankreatische Nebenmilz imitiert NET mit falsch positivem Somatostatin-Rezeptor-PET/CT (68Ga-DOTA-TOC-PET/CT).","authors":"Saher Saeed, Ioannis Dimopoulos, Nehara Begum, Jan Robert Kröger","doi":"10.1055/a-2166-7025","DOIUrl":"10.1055/a-2166-7025","url":null,"abstract":"","PeriodicalId":94161,"journal":{"name":"Nuklearmedizin. Nuclear medicine","volume":"63 2","pages":"78-80"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140290030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Robert Freudenberg, David Kästner, Jörg Kotzerke, Claudia Brogsitter
{"title":"[Evaluation of risk analysis in treatment with unsealed radioactive substances in nuclear medicine].","authors":"Robert Freudenberg, David Kästner, Jörg Kotzerke, Claudia Brogsitter","doi":"10.1055/a-2237-8639","DOIUrl":"10.1055/a-2237-8639","url":null,"abstract":"","PeriodicalId":94161,"journal":{"name":"Nuklearmedizin. Nuclear medicine","volume":" ","pages":"62-68"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10963124/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139543855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sebastian E Serfling, Andreas Buck, Steven P Rowe, Takahiro Higuchi, Rudolf Werner
{"title":"Red Bull PET/CT.","authors":"Sebastian E Serfling, Andreas Buck, Steven P Rowe, Takahiro Higuchi, Rudolf Werner","doi":"10.1055/a-2195-0138","DOIUrl":"10.1055/a-2195-0138","url":null,"abstract":"<p><p>We report on a patient diagnosed with Hodgkin Lymphoma who was scheduled for [<sup>18</sup>F]FDG PET/CT as part of routine follow-up after treatment with two cycles of chemotherapy and mediastinal external beam radiation. Although the patient was advised to fast for at least four hours, an energy drink (Red Bull ) was ingested right after radiotracer administration, which led to increased uptake in the large skeletal muscles, thereby rendering this scan as non-diagnostic. After strictly following respective dietary recommendations, the repeated scan then provided excellent image quality and revealed response to treatment. In the present case report, we discuss the impact of major ingredients (sugar, caffeine, taurine, glucuronolactone) of Red Bull on large muscle uptake, which may also apply to \"sugar-free\" types of this popular energy drink. Moreover, this case reports demonstrates the importance to inform patients that they should avoid intake of energy drinks not only prior to but also after injection of [<sup>18</sup>F]FDG.</p>","PeriodicalId":94161,"journal":{"name":"Nuklearmedizin. Nuclear medicine","volume":" ","pages":"76-77"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10963125/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138886847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Rudolf Werner, Alexander Haug, Christian Buske, Simon Heidegger, Anna L Illert, Florian Bassermann, Peter Herhaus, Andreas Buck, Johannes Duell, Max S Topp, Sabrina Kraus, Hermann Einsele, Constantin Lapa, Markus Raderer, Georg Lenz, Stefan Habringer, Bastian von Tresckow, Ulrich Keller
{"title":"CXCR4-targeted Theranostics in Hematooncology: Opportunities and Challenges.","authors":"Rudolf Werner, Alexander Haug, Christian Buske, Simon Heidegger, Anna L Illert, Florian Bassermann, Peter Herhaus, Andreas Buck, Johannes Duell, Max S Topp, Sabrina Kraus, Hermann Einsele, Constantin Lapa, Markus Raderer, Georg Lenz, Stefan Habringer, Bastian von Tresckow, Ulrich Keller","doi":"10.1055/a-2194-9965","DOIUrl":"10.1055/a-2194-9965","url":null,"abstract":"<p><p>C-X-C motif chemokine receptor 4 (CXCR4) is overexpressed in a multitude of cancers, including neoplasms of hematopoietic origin. This feature can be leveraged by a theranostic approach, which provides a read-out of the actual CXCR4 expression in vivo, followed by CXCR4-targeted radioligand therapy (RLT) exerting anti-cancer as well as myeloablative efficacy. In a recent meeting of hematooncology and nuclear medicine specialists, statements on the current clinical practice and future perspectives of this innovative concept were proposed and summarized in this opinion article. Experts concluded that i) CXCR4-directed [68Ga]Ga-PentixaFor PET/CT has the potential to improve imaging for patients with marginal zone lymphoma; ii) CXCR4-targeted RLT exerts anti-lymphoma efficacy and myeloablative effects in patients with advanced, treatment-refractory T-cell lymphomas; iii) prospective trials with CXCR4-based imaging and theranostics are warranted.</p>","PeriodicalId":94161,"journal":{"name":"Nuklearmedizin. Nuclear medicine","volume":" ","pages":"57-61"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10963126/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139405801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Florian Wedel, Thomas Exarchopoulos, Winfried Brenner
{"title":"Predictive factors for the outcome of radioiodine therapy in patients with benign thyroid diseases.","authors":"Florian Wedel, Thomas Exarchopoulos, Winfried Brenner","doi":"10.1055/a-2191-3113","DOIUrl":"10.1055/a-2191-3113","url":null,"abstract":"<p><strong>Purpose: </strong>Radioiodine therapy (RIT) of benign thyroid diseases is an established therapy. This study aimed to identify factors predictive for outcome in patients with non-toxic goiter (NTG), unifocal (UFA), multifocal (MUFA) or diffuse autonomy (DISA) and Graves' disease (GD).</p><p><strong>Methods: </strong>Retrospective analysis of 205 patients with benign thyroid disease (54 NTG, 46 MUFA, 24 DISA, 26 UFA, 55 GD) who underwent RIT. Follow up time was 12 months for determining treatment outcome.</p><p><strong>Results: </strong>The type of disease was predictive for volume reduction after 12 months (NTS 66%, DISA 67%, MUFA 58%, UFA 51%, GD 71%, p<0.001) and post-treatment hypothyroidism (NTS 48%, DISA 33%, MUFA 15%, UFA 15%, p=0.006). Initial volume, intra-therapeutic uptake and intra-therapeutic half-life were independent prognostic factors for volume reduction 12 months after RIT. In patients with NTG, UFA, MUFA, DISA post-treatment hypothyroidism was significantly correlated with extent of volume reduction 12 months after RIT, achieved dose, higher pre-therapeutic TSH values and younger age. Two different strategies for pre-therapeutic dosimetry used in MUFA showed no differences regarding the therapeutic outcome. In GD, effective half-life, initial volume and Graves' ophthalmopathy were predictive for treatment failure.</p><p><strong>Conclusion: </strong>Reduction of thyroid volume and the percentage of hypothyroid patients one year after RIT was primarily dependent on the type of disease. In MUFA and DISA we could identify volume reduction after 3 months as a reliable predictor for hypothyroidism while in patients with GD a short intra-therapeutic half-life, a large pre-therapeutic volume and active Graves' ophtalmopathy were relevant predictors for treatment failure suggesting an intensified follow-up scheme in these patients.</p>","PeriodicalId":94161,"journal":{"name":"Nuklearmedizin. Nuclear medicine","volume":" ","pages":"69-75"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139405805","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sean Ira G Gacula, Sophie C Kunte, Lena M Unterrainer, Johannes Rübenthaler, Wolfgang G Kunz, Clemens Cyran, Adrien Holzgreve
{"title":"Correction: Divergent growth on [18F]FDG PET/CT in a case of co-existing pulmonary metastatic leiomyosarcoma and papillary thyroid carcinoma.","authors":"Sean Ira G Gacula, Sophie C Kunte, Lena M Unterrainer, Johannes Rübenthaler, Wolfgang G Kunz, Clemens Cyran, Adrien Holzgreve","doi":"10.1055/a-2286-9571","DOIUrl":"https://doi.org/10.1055/a-2286-9571","url":null,"abstract":"","PeriodicalId":94161,"journal":{"name":"Nuklearmedizin. Nuclear medicine","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140290029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sean Ira G Gacula, Sophie C Kunte, Lena M Unterrainer, Johannes Rübenthaler, Wolfgang G Kunz, Clemens Cyran, Adrien Holzgreve
{"title":"Divergent growth on [18F]FDG PET/CT in a case of co-existing pulmonary metastatic leiomyosarcoma and papillary thyroid carcinoma.","authors":"Sean Ira G Gacula, Sophie C Kunte, Lena M Unterrainer, Johannes Rübenthaler, Wolfgang G Kunz, Clemens Cyran, Adrien Holzgreve","doi":"10.1055/a-2273-2447","DOIUrl":"10.1055/a-2273-2447","url":null,"abstract":"","PeriodicalId":94161,"journal":{"name":"Nuklearmedizin. Nuclear medicine","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140103114","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Correction: 18F-FDG PET/CT images of adult pulmonary blastoma: a case report.","authors":"Minhan Chen, Yao Liu","doi":"10.1055/a-2265-4049","DOIUrl":"10.1055/a-2265-4049","url":null,"abstract":"","PeriodicalId":94161,"journal":{"name":"Nuklearmedizin. Nuclear medicine","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139914368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Nonosseous bone seeking tracer focal uptake in the conventional scintigraphy.","authors":"Manfred Fischer, Jan Schneider-Eicke","doi":"10.1055/a-2198-0684","DOIUrl":"10.1055/a-2198-0684","url":null,"abstract":"","PeriodicalId":94161,"journal":{"name":"Nuklearmedizin. Nuclear medicine","volume":" ","pages":"45-47"},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138296812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}